Brokerages Set Selecta Biosciences Inc. (SELB) Price Target at $30.00

Selecta Biosciences Inc. (NASDAQ:SELB) has earned a consensus recommendation of “Hold” from the six research firms that are covering the firm, Marketbeat reports. Two investment analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation, two have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $30.00.

SELB has been the topic of a number of research analyst reports. Mizuho reiterated a “buy” rating and issued a $30.00 target price on shares of Selecta Biosciences in a research report on Wednesday, April 11th. Zacks Investment Research downgraded Selecta Biosciences from a “hold” rating to a “strong sell” rating in a research report on Wednesday, March 21st. Canaccord Genuity reiterated a “buy” rating on shares of Selecta Biosciences in a research report on Wednesday, January 3rd. ValuEngine downgraded Selecta Biosciences from a “sell” rating to a “strong sell” rating in a research report on Friday, February 2nd. Finally, BidaskClub upgraded Selecta Biosciences from a “buy” rating to a “strong-buy” rating in a research report on Thursday, March 15th.

How to Become a New Pot Stock Millionaire

Hedge funds and other institutional investors have recently modified their holdings of the business. Stanley Laman Group Ltd. bought a new stake in Selecta Biosciences during the fourth quarter worth approximately $402,000. Alps Advisors Inc. bought a new stake in Selecta Biosciences during the fourth quarter worth approximately $243,000. Allianz Asset Management GmbH bought a new stake in Selecta Biosciences during the fourth quarter worth approximately $485,000. Wasatch Advisors Inc. increased its stake in Selecta Biosciences by 100.6% during the fourth quarter. Wasatch Advisors Inc. now owns 246,618 shares of the company’s stock worth $2,419,000 after acquiring an additional 123,695 shares during the last quarter. Finally, SG Americas Securities LLC bought a new stake in Selecta Biosciences during the fourth quarter worth approximately $145,000. 50.15% of the stock is currently owned by institutional investors.

Shares of Selecta Biosciences stock traded down $0.05 during trading hours on Tuesday, hitting $12.36. The company’s stock had a trading volume of 193,367 shares, compared to its average volume of 422,361. Selecta Biosciences has a 12-month low of $7.95 and a 12-month high of $24.02. The company has a market capitalization of $276.25, a price-to-earnings ratio of -3.86 and a beta of -3.56. The company has a quick ratio of 9.00, a current ratio of 9.00 and a debt-to-equity ratio of 0.41.

Selecta Biosciences (NASDAQ:SELB) last announced its quarterly earnings data on Thursday, March 15th. The company reported ($0.88) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.56) by ($0.32). Selecta Biosciences had a negative net margin of 31,556.04% and a negative return on equity of 110.64%. The business had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $15.00 million. equities analysts expect that Selecta Biosciences will post -3.28 earnings per share for the current year.

WARNING: “Brokerages Set Selecta Biosciences Inc. (SELB) Price Target at $30.00” was published by Week Herald and is the sole property of of Week Herald. If you are reading this article on another publication, it was stolen and reposted in violation of United States & international copyright laws. The correct version of this article can be viewed at https://weekherald.com/2018/04/22/brokerages-set-selecta-biosciences-inc-selb-price-target-at-30-00.html.

About Selecta Biosciences

Selecta Biosciences, Inc, a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its proprietary pipeline includes synthetic vaccine particles (SPV)-enabled enzyme, oncology, and gene therapies. The company's lead product is SEL-212 that in Phase II clinical trial to treat severe gout patients and resolve their symptoms, including flares and gouty arthritis.

Receive News & Ratings for Selecta Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply